The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Autoimmune Diseases Common in Patients with Vitiligo

Autoimmune Diseases Common in Patients with Vitiligo

November 19, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients with vitiligo commonly have other autoimmune diseases, according to a cross-sectional study.

You Might Also Like
  • Type 1 Diabetes Often Comes with Other Autoimmune Diseases
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • Parkinson’s, Autoimmune Disorders May Share Genetic Common Ground

“Vitiligo is a systemic disease with multiple comorbidities,” Dr. Iltefat Hamzavi from Henry Ford Hospital in Detroit, Mich., told Reuters Health by email. “The number of patients with neurologic diseases and inflammatory disease was much higher than we anticipated.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Vitiligo, with an estimated prevalence ranging from 0.5% to 1%, is characterized by selective loss of melanocytes and patchy depigmentation of the skin and mucous membranes. Autoimmunity is thought to play a role in its pathogenesis.

Based on a manual chart review involving nearly 1,100 patients with vitiligo, Dr. Hamzavi and colleagues found that 19.8% had at least one comorbid autoimmune disease, and 2.8% had more than one, they report in the Journal of the American Academy of Dermatology, online Oct. 27.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The two most common comorbid autoimmune diseases were thyroid disease (12.3% of patients) and alopecia areata (3.8% of patients).

Other autoimmune diseases with significantly increased prevalence (compared with the general population) included discoid lupus, Guillain-Barre syndrome, linear morphea, myasthenia gravis, pernicious anemia, Sjogren syndrome and systemic lupus erythematosus (SLE).

Female patients with vitiligo had a higher prevalence of comorbid thyroid disease than did male patients with vitiligo (18.5% vs. 5.1%; p<0.001), but there were no other differences between the sexes.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with at least one comorbid autoimmune disease tended to have more extensive vitiligo, compared with those who had no comorbid autoimmune disease.

“This builds on the theory pointing to an autoimmune pathogenesis for vitiligo,” Dr. Hamzavi says. “Most patients with vitiligo will not develop autoimmune disease, but a significant minority will develop hypothyroidism. Patients with vitiligo should be regularly screened yearly for thyroid disorders.”

“Also the rates of other autoimmune diseases like alopecia areata, inflammatory bowel disease, Guillain Barre, SLE (lupus), and others were observed at a much higher rate than one would expect,” Dr. Hamzavi says. “Patients should be asked if they have symptoms of these diseases when evaluated by their physicians.”

“We need better treatments for vitiligo which target the cause of the disease,” Dr. Hamzavi adds. “We hope that this work can be used by patients, physicians and researchers toward that end.”

“Prospective studies of vitiligo with a control group are needed to confirm the significance of our findings and may help uncover the sequence of development of these conditions,” the authors conclude.

Dr. Katia Boniface from Universite de Bordeaux in France, who was not involved in the new work, has studied the immune mechanisms of vitiligo. She told Reuters Health by email, “It is an interesting clinical study supporting previous findings demonstrating that an important proportion of vitiligo patients display at least one other comorbid autoimmune disease, in favor of the autoimmune theory to explain melanocyte disappearance in this disease.”

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Autoimmune disease, comorbidities, skin, vitiligo

You Might Also Like:
  • Type 1 Diabetes Often Comes with Other Autoimmune Diseases
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • Parkinson’s, Autoimmune Disorders May Share Genetic Common Ground
  • Cutaneous Lupus Tied to Risk for Coexisting Autoimmune Conditions

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.